Introduction {#s1}
============

Breast cancer is the commonest cancer worldwide and second to cervical cancer in women mortality [@pone.0071073-Hortobagyi1]. A large number of environmental and genetic factors are known to play an important role in breast cancer development and prognosis. In recent years, several breast cancer susceptibility genes have been identified with BRCA1 and BRCA2 are major genes related to 15% of hereditary breast cancer cases [@pone.0071073-Peto1], [@pone.0071073-1]. Thus, further studies are needed to identify other genes having an impact on breast cancer risk and prognosis which may likely to play a major role in risk prediction.

Breast cancers contain few distinct cells called breast cancer-initiating cells (BCICs), which are characterized by the expression of CIC biomarkers [@pone.0071073-Lobo1]. *CD44* is one such biomarker. *CD44* gene is located on chromosome 11p13 [@pone.0071073-Goodfellow1]. The encoded protein is a cell surface glycoprotein, involved in a number of biological processes including lymphocyte migration, extravasation, homing, activation and apoptosis [@pone.0071073-Bourguignon1], [@pone.0071073-Seth1], [@pone.0071073-Rafi1], [@pone.0071073-Chen1], [@pone.0071073-AlHajj1], [@pone.0071073-McKallip1], [@pone.0071073-McKallip2], [@pone.0071073-Sales1]. Many studies have also stated its role in tumor metastasis [@pone.0071073-Marhaba1], [@pone.0071073-Hill1]. It is also a receptor for hyaluronic acid. Recent studies have shown *CD44* and its interaction with hyaluronan regulate breast cancer cell proliferation, migration and invasion. In addition genetic variants of *CD44* were found to be associated with breast cancer patient survival, risk prediction and prognosis [@pone.0071073-Jiang1], [@pone.0071073-Gotte1], [@pone.0071073-Xin1].

SNP rs13347 was previously reported to be significantly associated with breast cancer risk and prognosis in Chinese population [@pone.0071073-Jiang1]. However, in view of limited studies [@pone.0071073-Jiang1], [@pone.0071073-Xin1], [@pone.0071073-Zhou1], we aimed to determine the association of previously significant reported SNP (rs13347), together with taggerSNP (rs353639) in the *CD44* gene of Hapmap- GIH population with breast cancer risk and prognosis in North Indian population.

Materials and Methods {#s2}
=====================

Ethics Statement {#s2a}
----------------

The study including the consent process was approved by the ethics committee of Sanjay Gandhi Post Graduate Institute of Medical Sciences (SGPGIMS), Lucknow, India and the authors followed the norms of World's Association Declaration of Helsinki. Written informed consent was taken from each subject.

Study Population {#s2b}
----------------

The present study consisted of 258 histopathologically confirmed breast cancer patients from north Indian population. Patients were enrolled from the outpatient department (OPD) of Endocrine & Breast Surgery, and Radiotherapy, SGPGIMS, Lucknow, who have completed their treatment as planned between the period from April, 2010 to Oct, 2012. The patients were subjected to detailed demographical, clinical and pathological investigations. Staging of cancer was documented according to the AJCC-TNM classification system [@pone.0071073-Edge1]. During the same time, age and ethnicity matched 241 healthy controls were recruited from volunteers who came to the hospital for their routine checkups, unrelated to patients and to each other. Selection criteria for controls included no evidence of any personal history of cancer or other malignant conditions.

Out of 258 patients, neo-adjuvant chemotherapy (NACT) was administered to 114 locally advanced or large operable breast cancer (LOBC or LABC) patients. Therefore, case-control study for evaluating breast cancer risk was done in 258 patients while 114 patients were recruited in case only study for evaluation of response to NACT. Pathological response to NACT was recorded according to Response Evaluation Criteria in Solid Tumors (RECIST criteria) [@pone.0071073-Therasse1] and patients were categorized as pathologic complete responders (≥30% tumour regression) and non pathologic responders (\<30% tumour regression).

TagSNPs Selection {#s2c}
-----------------

TagSNPs were selected from the Haploview software 4.2 (Mark Daly's lab of Broad Institute, Cambridge, MA, Britain) [@pone.0071073-Barrett1], based on the GIH population data of HapMap (HapMap Data Rel 27 PhaseII +III, Feb 09, on NCBI B36 assembly, dbSNP b126). TagSNPs that captured all the known common SNPs (with minor allele frequencies of \>0.1) in the *CD44* gene, with a pairwise correlation r^2^\>0.8 were selected.

TaggerSNP rs 353639 was found to represent the known SNPs in the haplotype blocks 3 and 4 in the *CD44* gene of GIH population ([Figure S1](#pone.0071073.s001){ref-type="supplementary-material"}). It was also found to represent the haplotype block 5 in Caucasian (CEU in Hapmap) population ([Figure S1](#pone.0071073.s001){ref-type="supplementary-material"}). Previously significantly reported SNP (rs13347) in Chinese population also represents the haplotype block 9 ([Figure 1](#pone-0071073-g001){ref-type="fig"}).

![Linkage disequilibrium (LD) plot of *CD44* gene in Hapmap- GIH population.](pone.0071073.g001){#pone-0071073-g001}

Genotyping {#s2d}
----------

Genomic DNA was extracted from the venous blood using the standard salting out method [@pone.0071073-Miller1]. The quality and quantity of DNA was checked by using Nanodrop spectrophotometer (Thermo Fisher Scientific/Nanodrop Products, Wilmington, Delaware, USA). Genotyping of both the SNPs: rs13347 and rs353639 was carried out using Taqman allelic discrimination assay. Primers and probes were supplied as pre-designed assays by Applied Biosystems (Foster City, CA, USA). Genotyping was performed on an ABI 7500 Real Time PCR system using 96-well plates. All plates included negative controls (wells containing no DNA). ABI PRISM 7500 sequence detection software was used for amplification detection.

Statistical Analysis {#s2e}
--------------------

Effective sample sizes for case-control study was calculated by Quanto 1.1 ver. software and the power was set at 80% [@pone.0071073-Gauderman1]. Descriptive statistics of patients and controls were presented as the mean and standard deviations (SDs) for continuous measures, while frequencies and percentages were used for categorical measures. The null hypothesis that the Hardy--Weinberg equilibrium holds was tested using a chi-squared test for deviation from Hardy--Weinberg equilibrium. The relationship between genetic variants and clinicopathological features along with breast cancer treatment response was examined using univariate analysis through Fisher's exact test. Similarly, multivariate analysis was also performed by using binary logistic regression. Clinicopathological features included in the analysis were age, tumor size, HER2 status, hormone receptor status, histology, grade and nodal status. All statistical analysis was done using SPSS statistical analysis software, version 17.0 (SPSS, Chicago, IL, USA). Association was expressed as odds ratios (OR) with 95% confidence intervals (CI). The association was considered to be significant when the *P*-value was \<0.05.

In Silico Analysis {#s2f}
------------------

The possible functional effects were determined in *CD44* gene by online web servers FASTSNP (<http://fastsnp.ibms.sinica.edu.tw>) and F-SNP (<http://compbio.cs.queensu.ca/F-SNP/>) [@pone.0071073-Yuan1], [@pone.0071073-Lee1].

Results {#s3}
=======

Population Characteristics {#s3a}
--------------------------

The detailed demographic, clinical and pathological characteristics of study subjects were illustrated in [Table 1](#pone-0071073-t001){ref-type="table"}.

10.1371/journal.pone.0071073.t001

###### Characteristics of the study population.

![](pone.0071073.t001){#pone-0071073-t001-1}

  Characteristics                              258 Cases     241 Controls
  --------------------------- -------------- -------------- --------------
  Age (mean±SD)                               49.47±11.082   47.42±10.385
  Menstrual status                 Pre         98 (38.0)      127 (52.7)
                                   Post        160 (62.0)     114 (47.3)
  Histology                       Ductal       242 (93.8)   
                                 Lobular        4 (1.6)     
                                  Mixed         8 (3.1)     
                               Missing data     4 (1.6)     
  Grade (G)                      Negative       11 (4.3)    
                                    G2         144 (55.8)   
                                    G3         96 (37.2)    
                               Missing data     7 (2.7)     
  Clinical tumour size (cm)         0           3 (1.2)     
                                   \<2          22 (8.5)    
                                 2.1--5.0      119 (46.1)   
                                  \>5.0        94 (36.4)    
                               Missing data     20 (7.8)    
  Clinical lymph node               0          87 (33.7)    
                                   \<3         102 (39.5)   
                                   4--9        48 (18.6)    
                                   \>10         10 (3.9)    
                               Missing data     11 (4.3)    
  Metastasis                        M0         240 (93.8)   
                                    M1          16 (6.2)    
  Hormone Receptor               Positive      117 (45.3)   
                                 Negative      136 (52.7)   
                               Missing data     5 (2.0)     
  Her 2 neu expression           Positive      91 (35.3)    
                                 Negative      150 (58.1)   
                               Missing data     17 (6.6)    
  Treatment given                  NACT        114 (44.2)   
                                   ACT         130 (50.4)   
                               Missing data     14 (5.4)    

*CD44* gene Polymorphisms with Breast Cancer Risk {#s3b}
-------------------------------------------------

The observed genotype frequencies of the two polymorphisms studied in healthy controls were in accordance with Hardy-Weinberg equilibrium.

[Table 2](#pone-0071073-t002){ref-type="table"} shows the risk of breast cancer in context with each of the SNPs studied in *CD44* gene. No significant differences were observed in the frequency distribution of rs13347 and rs353639 polymorphisms between breast cancer patients and healthy controls, both at the genotypic and allelic levels. Further analyzing our study subjects on stratification based on menstrual status, we did not find significant correlations of the genotypes as well as alleles of both the polymorphisms with breast cancer risk.

10.1371/journal.pone.0071073.t002

###### Association of rs13347 and rs353639 polymorphisms with breast cancer risk.

![](pone.0071073.t002){#pone-0071073-t002-2}

  Genotypes/Alleles     Overall     Premenopausal    Postmenopausal                                                                                                                  
  ------------------- ------------ --------------- ------------------- ------- ------------ ------------ -------------------- ------- ------------ ------------ -------------------- -------
  rs13347                                                                                                                                                                            
  CC                   191 (74.0)    178 (73.9)       1 (Reference)      --     71 (72.4)     96(75.6)      1 (Reference)       --     120 (75.0)   82 (71.9)      1 (Reference)       --
  CT                   60 (23.3)      57 (23.7)     1.00 (0.65--1.53)   0.983   24 (24.5)    29 (22.8)    1.15 (0.61--2.15)    0.659   36 (22.5)    28 (24.6)    0.87 (0.48--1.56)    0.645
  TT                    7 (2.7)        6 (2.5)      1.16 (0.37--3.60)   0.792    3 (3.1)      2 (1.6)     2.22 (0.35--13.80)   0.392    4 (2.5)      4 (3.5)     0.74 (0.17--3.06)    0.678
  CT+TT                67 (26.0)      63 (26.1)     1.02 (0.67--1.53)   0.926   27 (27.6)     31(24.4)    1.21 (0.66--2.22)    0.527   40 (25.0)    32 (28.1)    0.856 (0.49--1.49)   0.582
  C                    442 (85.7)    413 (85.7)       1 (Reference)      --     166 (84.7)   221 (87.0)     1 (Reference)       --     276 (86.2)   192 (84.2)     1 (Reference)       --
  T                    74 (14.3)      69 (14.3)     1.03 (0.71--1.48)   0.867   30 (15.3)     33(13.0)    1.25 (0.73--2.13)    0.416   44 (13.8)    36 (15.8)    0.85 (0.52--1.39)    0.540
  rs353639                                                                                                                                                                           
  AA                   158 (61.2)    150 (61.2)       1 (Reference)      --     60 (61.2)    76 (59.8)      1 (Reference)       --     98 (61.2)    74 (64.9)      1 (Reference)       --
  AC                   89 (34.5)      89 (34.5)     1.16 (0.78--1.70)   0.451   35 (35.7)    45 (35.4)    0.99 (0.56--1.73)    0.978   54 (33.8)    33 (28.9)    1.36 (0.79--2.34)    0.263
  CC                    11 (4.3)      13 (5.4)      0.75 (0.31--1.77)   0.514    3 (3.1)      6 (4.7)     0.65 (0.15--2.73)    0.560    8 (5.0)      7 (6.1)     0.78 (0.26--2.31)    0.657
  AC+CC                100 (38.8)     91 (37.8)     1.09 (0.75--1.59)   0.618   38 (38.8)    51 (40.2)    0.95 (0.55--1.63)    0.862   62 (38.8)    40 (35.1)    1.25 (0.75--2.08)    0.387
  A                    405 (78.5)    378 (78.4)       1 (Reference)      --     155 (79.1)   197 (77.6)     1 (Reference)       --     250 (78.1)   181 (79.4)     1 (Reference)       --
  C                    111 (21.5)    104 (21.6)     1.02 (0.75--1.39)   0.897   41 (20.9)    57 (22.4)    0.92 (0.58--1.45)    0.731   70 (21.9)    47 (20.6)    1.10 (0.72--1.69)    0.636

OR = Odd's Ratio; CI = Confidence Interval.

\#OR adjusted by age.

*CD44* gene polymorphisms with Breast Cancer Prognosis {#s3c}
------------------------------------------------------

Univariate analysis by Fisher's exact test and Multivariate by logistic regression was employed to correlate the genotypes of the two *CD44* polymorphisms with the clinicopathological features and breast cancer pathologic response to NACT.

In univariate analysis, we found significant correlations of genotype (CT+TT) of rs13347 polymorphism with earlier age of onset (P = 0.029, OR = 0.037) ([Table 3](#pone-0071073-t003){ref-type="table"}). However, we could not find any association at the allelic level ([Table 3](#pone-0071073-t003){ref-type="table"}). The data also revealed significant association of rs353639 polymorphism with clinical tumour size, both at the genotypic (AC+CC) (P = 0.039, OR = 3.02) as well as the allelic (P = 0.042, OR = 2.87) levels ([Table 4](#pone-0071073-t004){ref-type="table"}).

10.1371/journal.pone.0071073.t003

###### Univariate analysis of the association of rs13347 polymorphism with breast cancer clinicopathological features and treatment response.

![](pone.0071073.t003){#pone-0071073-t003-3}

                               rs13347                                                                                                        
  --------------------------- ---------- ----------- ----------- ------------------- ----------- ------------ ----------- ------------------- -------
  Age (years)                    ≤45      27 (62.8)   16 (37.2)     1 (Reference)        --       70 (81.4)    16 (18.6)     1 (Reference)      --
                                 \>45     58 (81.7)   13 (18.3)   0.37 (0.16--0.89)   **0.029**   127 (89.4)   15 (10.6)   0.51 (0.24--1.10)   0.110
  Clinical Tumour size (cm)      \<5      25 (86.2)   4 (13.8)      1 (Reference)        --       54 (93.1)     4 (6.9)      1 (Reference)      --
                                 \>5      53 (70.7)   22 (29.3)   2.59 (0.80--8.33)     0.132     126 (84.)    24 (16.0)   2.57 (0.85--7.76)   0.112
  Clinical lymph node          Negative   7 (70.0)    3 (30.0)      1 (Reference)        --       17 (85.0)    3 (15.0)      1 (Reference)      --
                               Positive   74 (74.0)   26 (26.0)   0.82 (0.19--3.40)     0.722     172 (86.0)   28 (14.0)   0.92 (0.25--3.35)   1.000
  Hormone Receptor             Negative   39 (75.0)   13 (25.0)     1 (Reference)        --       91 (87.5)    13 (12.5)     1 (Reference)      --
                               Positive   46 (75.4)   15 (24.6)   0.97 (0.41--2.30)     1.000     105 (86.1)   17 (13.9)   1.13 (0.52--2.45)   0.845
  Her 2 neu expression         Negative   50 (75.8)   16 (24.2)     1 (Reference)        --       115 (87.1)   17 (12.9)     1 (Reference)      --
                               Positive   32 (74.4)   11 (25.6)   1.07 (0.44--2.60)     1.000     74 (86.0)    12 (14.0)   1.09 (0.49--2.42)   0.840
  Grade                         G1+G2     49 (76.6)   15 (23.4)     1 (Reference)        --       112 (87.5)   16 (12.5)     1 (Reference)      --
                                  G3      36 (72.0)   14 (28.0)   1.27 (0.54--2.96)     0.666     85 (85.0)    15 (15.0)   1.23 (0.57--2.63)   0.698
  Treatment Response             pCR      52 (76.5)   16 (23.5)     1 (Reference)        --       119 (87.5)   17 (12.5)     1 (Reference)      --
                                No pCR    33 (71.7)   13 (28.3)   1.28 (0.54--3.00)     0.662     78 (84.8)    14 (15.2)   1.25 (0.58--2.69)   0.561

OR = Odd's Ratio; CI = Confidence Interval; Significant P value \<0.05 is given in bold.

pCR = pathologic complete response.

Fisher's exact test.

10.1371/journal.pone.0071073.t004

###### Univariate analysis of the association of rs353639 polymorphism with breast cancer clinicopathological features and treatment response.
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                               rs353639                                                                                                       
  --------------------------- ---------- ----------- ----------- ------------------- ----------- ------------ ----------- ------------------- -----------
  Age (years)                    \<45     31 (72.1)   12 (27.9)     1 (Reference)        --       72 (83.7)    14 (16.3)     1 (Reference)        --
                                 \>45     44 (62.0)   27 (38.0)   1.58 (0.69--3.60)     0.312     112 (78.9)   30 (21.1)   1.37 (0.68--2.77)     0.393
  Clinical Tumour size (cm)      \<5      24 (82.8)   5 (17.2)      1 (Reference)        --       53 (91.4)     5 (8.6)      1 (Reference)        --
                                 \>5      46 (61.3)   29 (38.7)   3.02 (1.03--8.82)   **0.039**   118 (78.7)   32 (21.3)   2.87 (1.06--7.78)   **0.042**
  Clinical lymph node          Negative   5 (50.0)    5 (50.0)      1 (Reference)        --       15 (75.0)    5 (25.0)      1 (Reference)        --
                               Positive   67 (67.0)   33 (33.0)   0.49 (0.13--1.82)     0.310     162 (81.0)   38 (19.0)   0.70 (0.24--2.05)     0.555
  Hormone Receptor             Negative   34 (65.4)   18 (34.6)     1 (Reference)        --       83 (79.8)    21 (20.2)     1 (Reference)        --
                               Positive   40 (65.6)   21 (34.4)   0.99 (0.65--1.51)     1.000     99 (81.1)    23 (18.9)   0.91 (0.47--1.77)     0.867
  Her 2 neu expression         Negative   44 (66.7)   22 (33.3)     1 (Reference)        --       108 (81.8)   24 (18.2)     1 (Reference)        --
                               Positive   28 (65.1)   15 (34.9)   1.07 (0.47--2.40)     1.000     69 (80.2)    17 (19.8)   1.10 (0.55--2.21)     0.860
  Grade                         G1+G2     41 (64.1)   23 (35.9)     1 (Reference)        --       102 (79.7)   26 (20.3)     1 (Reference)        --
                                  G3      34 (68.0)   16 (32.0)   0.83 (0.38--1.83)     0.695     82 (82.0)    18 (18.0)   0.86 (0.44--1.67)     0.736
  Treatment Response             pCR      46 (67.6)   22 (32.4)     1 (Reference)        --       111 (81.6)   25 (18.4)     1 (Reference)        --
                                No pCR    29 (63.0)   17 (37.0)   1.22 (0.55--2.68)     0.689     73 (79.3)    19 (20.7)   1.15 (0.59--2.24)     0.733

OR = Odd's Ratio; CI = Confidence Interval; Significant P values \<0.05 are given in bold.

pCR = pathologic complete response.

Fisher's exact test.

Next, we performed a multivariate analysis using a logistic regression to evaluate the correlations of both the *CD44* gene polymorphisms with the clinicopathological features and breast cancer treatment response to NACT. In rs13347 polymorphism, we observed that significant association of genotypes with earlier age of onset was lost on applying multivariate analysis ([Table 5](#pone-0071073-t005){ref-type="table"}). No significant association of the alleles with any of the clinicopathological features as well as treatment response was seen ([Table 5](#pone-0071073-t005){ref-type="table"}). On analyzing the data in rs353639 polymorphism with logistic regression, we found increased significance of both the genotype (P = 0.017, OR = 4.29) as well as allele (P = 0.025, OR = 3.34) with clinical tumour size when compared with the results of univariate analysis ([Table 6](#pone-0071073-t006){ref-type="table"}). However, no significant association of both the polymorphisms was seen with treatment response to NACT.

10.1371/journal.pone.0071073.t005

###### Multivariate analysis of the association of rs13347polymorphism with breast cancer clinicopathological features and treatment response.
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                                                       rs13347                                   
  ---------------------------------------------- ------------------- ------- ------------------- -------
  Age (\>45 years vs. \<45years)                  0.70 (0.26--1.84)   0.473   0.91 (0.38--2.16)   0.832
  Clinical Tumour size (\>5cm vs. \<5cm)          2.62 (0.76--9.06)   0.126   2.74 (0.85--8.79)   0.089
  Clinical lymph node (positive vs. negative)     0.56 (0.12--2.610   0.466   0.63 (0.16--2.51)   0.520
  Hormone Receptor (positive vs. negative)        1.05 (0.37--2.91)   0.924   1.30 (0.52--3.28)   0.569
  Her 2 neu expression (positive vs. negative)    1.09 (0.41--2.91)   0.853   1.13 (0.47--2.70)   0.776
  Grade (G2+G3 vs. G1)                            1.50 (0.54--4.16)   0.430   1.56 (0.63--3.86)   0.334
  Treatment Response (No pCR vs. pCR)             1.55 (0.58--4.15)   0.375   1.54 (0.64--3.68)   0.325

OR = Odd's Ratio; CI = Confidence Interval.

pCR = pathologic complete response.

10.1371/journal.pone.0071073.t006

###### Multivariate analysis of the association of rs353639 polymorphism with breast cancer clinicopathological features and treatment response.
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                                                       rs353639                                       
  ---------------------------------------------- -------------------- ----------- ------------------- -----------
  Age (\>45 years vs. \<45years)                  2.30 (0.87--6.06)      0.091     1.74 (0.76--3.98)     0.185
  Clinical Tumour size (\>5cm vs. \<5cm)          4.29 (1.30--14.11)   **0.017**   3.34 (1.16--9.59)   **0.025**
  Clinical lymph node (positive vs. negative)     0.29 (0.06--1.31)      0.109     0.48 (0.14--1.58)     0.229
  Hormone Receptor (positive vs. negative)        1.20 (0.44--3.21)      0.713     1.08 (0.47--2.510     0.844
  Her 2 neu expression (positive vs. negative)    1.26 (0.50--3.20)      0.616     1.21 (0.54--2.66)     0.635
  Grade (G2+G3 vs. G1)                            1.09 (0.40--2.92)      0.863     0.92 (0.39--2.18)     0.861
  Treatment Response (No pCR vs. pCR)             1.88 (0.73--4.81)      0.188     1.63 (0.74--3.58)     0.220

OR = Odd's Ratio; CI = Confidence Interval; Significant P values \<0.05 are given in bold.

pCR = pathologic complete response.

In Silico Analysis of *CD44* gene Polymorphisms {#s3d}
-----------------------------------------------

SNPs- rs13347 and rs353639 selected for the present study are located in 3′ UTR and intron region (non-coding sequences) of the *CD44* gene. Therefore, it was possible that this SNP may effect the transcription of the gene. In-silico analysis using F-SNP showed change in transcriptional regulation for both the selected SNPs ([Table 7](#pone-0071073-t007){ref-type="table"}).

10.1371/journal.pone.0071073.t007

###### In Silico analysis of *CD44* gene polymorphisms by F SNP and FAST SNP.
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  Polymorphisms              F SNP               FAST SNP                                                           
  --------------- ---------------------------- ------------ ----------- ------- ----------------------------------- ------------------------
  rs13347          Transcriptional regulation    TFSearch     changed    0.176   Downstream with no known function   Unknown-Unknown (0--0)
                                                GoldenPath   not exist                                              
  rs353639         Transcriptional regulation    TFSearch     changed    0.176    Intronic with no known function    Unknown-Unknown (0--0)
                                                GoldenPath   not exist                                              

Discussion {#s4}
==========

*CD44* is a transmembrane glycoprotein involved in many functions such as cell proliferation, angiogenesis, invasion and metastasis [@pone.0071073-So1]. *CD44* gene is composed of 20 exons [@pone.0071073-Goodfellow1] in two groups. One group consists of exons 1--5 and 16--20, which are expressed together whereas the other group has exons from 6--15. These 10 exons are alternatively spliced and can be included within the group one exons- 5 and 16. Multi-functional nature of the *CD44* depends on the binding of its ligand- hyaluronic acid [@pone.0071073-Screaton1]. There are two binding domains for hyaluronan- exon 2 and exon 5 [@pone.0071073-Telen1]. Interaction of *CD44* with hyaluronan is involved in the regulation of breast cancer through cell-cell adhesion and inhibited invasion [@pone.0071073-Lopez1]. However, altered binding of hyaluronan to *CD44* can activate cell growth, survival, invasion and metastasis in breast cancer [@pone.0071073-Bourguignon2], [@pone.0071073-Bourguignon3] as well as in other cancers [@pone.0071073-Vazquez1], [@pone.0071073-Winder1]. On the basis of above studies, we can state that *CD44* has a significant role in cancer development and prognosis. Therefore, the present study was carried out to evaluate the role of *CD44* gene polymorphisms in north Indian breast cancer patients.

Two polymorphisms within the *CD44* gene were studied to investigate the association of genetic variants with breast cancer risk prediction and prognosis. TaggerSNP approach was used to select the SNP (rs353639) that represents all known SNPs in the *CD44* gene of GIH population. The previously significant reported SNP (rs13347) in Chinese breast cancer patients was also selected to replicate the results in our population. *CD44* gene polymorphisms have not been widely studied with only few reports in breast cancer worldwide [@pone.0071073-Jiang1], [@pone.0071073-Gotte1], [@pone.0071073-Xin1], [@pone.0071073-Zhou1]. However till date, there is no report on influence of rs353639 polymorphism except a Genome-wide association report for subclinical atherosclerosis in the NHLBI\'s Framingham Heart Study [@pone.0071073-ODonnell1].

In this study, we sought to determine genetic variants of *CD44* that may confer individual's risk to breast cancer in 258 patients and 131 healthy controls. However, we did not observe any significant differences in the frequency distribution of the genetic variants *CD44* rs13347 between breast cancer patients and healthy controls. After stratification of our subjects on the basis of menstrual status also, no significant association was found. Our results are not in agreement with the single reported study on rs13347 polymorphism with susceptibility to breast cancer [@pone.0071073-Jiang1]. This study by Jiang et al., evaluated the variations in rs13347 polymorphism in 1,853 breast cancer patients and 1,992 healthy control subjects of Chinese population and variant genotype (CT+TT) conferred 1.72 times increased susceptibility to breast cancer. They also performed reporter assay to validate their findings and found variant genotype (CT+TT) carriers to have more *CD44* expression than wild type (CC) carriers. Reasons for variations in results can be due to difference in ethnicity and it is possible that another linked SNP of *CD44* may be conferring risk in our population.

Therefore, one taggerSNP (rs353639) in the *CD44* gene of GIH population was selected to evaluate the effect on breast cancer risk. However, we still found no significant association of rs353639 polymorphism with susceptibility to breast cancer. We also did not find any association on sub-group analysis based on menstrual status. However, no study on the role of rs353639 polymorphism in cancer risk has been reported. Therefore, reasons for discrepancy in the effect of *CD44* polymorphisms on breast cancer susceptibility may be because these polymorphisms have indirect role on breast cancer susceptibility. And their effects may possibly be mediated through linkage to some other key functional polymorphisms, especially in exon 2 and 5 regions of hyaluronan binding of CD44.

A study by Zhou et al., reported a unique SNP *CD44* Ex2+14 A\>G in the intron 1 region and found that patients with variant genotype had breast cancer at earlier ages, larger tumor burden, more regional lymph node metastasis and higher cancer recurrence [@pone.0071073-Zhou1]. Another study published by same author in 2012, identified 4 SNPs in exon 2 through sequencing and found significant association of the *CD44* polymorphisms in exon 2 coding sequence with higher probability and higher cumulative risk for breast cancer [@pone.0071073-Zhou2]. A recent study also showed significant increase in the *CD44* expression in breast cancer when compared to normal breast epithelium [@pone.0071073-Bankfalvi1]. Thus, based on conflicting findings, there is a need to replicate the above findings in larger sample size of different ethnicity to come to a definitive conclusion.

We also investigated the effect of genetic variants of *CD44* gene polymorphisms with clinicopathological features and pathologic response to NACT in a cohort of 114 patients. For rs13347 polymorphism, significant association of genotype (CT+TT) with earlier age of onset was found in univariate analysis but was lost on applying multivariate logistic regression. It therefore highlighted that genetic variants do not alone play a role in breast cancer development and prognosis. It is also necessary to evaluate the role of confounding factors like age, clinical stage, pathological lymph node, grade, hormone and Her 2 neu receptor along with these known variants. Similarly, no significant difference of genotype and allele of this polymorphism was seen with pathologic response to NACT. On the contrary, Yao et al, 2009 observed higher expression of *CD44* before chemotherapy in drug resistant cell lines than drug sensitive ones [@pone.0071073-Herui1]. A study by Zhou et al., reported variant genotype of *CD44* rs4756195 polymorphism to be associated with response to anthracyclines based chemotherapy in patients with breast cancer [@pone.0071073-Xin1].

For GIH tagger SNP rs353639, we found variant genotype (AC+CC) and allele (C) to be significantly associated with increased clinical tumour size. These results were consistent even after multivariate analysis. Our findings are in agreement with the concept that genetic variations in *CD44* gene may possibly effect the altered binding of its ligand- hyaluronan which leads to increased breast cancer cell growth and differentiation. The importance of this result was strengthened by performing bioinformatic analysis for prediction of functional effects for *CD44* rs353639 polymorphism. Possible functional mechanisms include altered *CD44* expression by differential binding of transcription factors.

Similar to rs13347 polymorphism, no association of genetic variants of *CD44* rs353639 polymorphism was seen with pathologic response to NACT. Therefore, influence of *CD44* gene polymorphisms in breast cancer treatment response to NACT is still not established.

Conclusions {#s4a}
-----------

Our study indicated that both the polymorphisms in *CD44* gene might not have any effect on breast cancer risk prediction in north Indian population. But these polymorphisms have definitely some implications in breast cancer prognosis. To our best knowledge, present study is the first to report a taggerSNP based selection of *CD44* gene polymorphisms with breast cancer risk and prognosis in North Indian subjects. However, study may require confirmation in larger population based cohorts. Furthermore, our findings need to be validated in breast cancer patients of different ethnicities with a gene expression functional assay.

Supporting Information {#s5}
======================

###### 

**Linkage disequilibrium (LD) plot of** ***CD44*** **gene in Hapmap- CEU population.**

(TIF)

###### 

Click here for additional data file.

The authors thank School of Telemedicine and Biomedical Informatics, SGPGIMS, Lucknow for bioinformatic assistance.

[^1]: **Competing Interests:**The authors have declared that no competing interests exist.

[^2]: Conceived and designed the experiments: BM. Performed the experiments: ST. Analyzed the data: ST. Contributed reagents/materials/analysis tools: GA PL SA. Wrote the paper: BM ST GA PL SA RDM.
